Stayble Therapeutics is dedicated to developing an effective treatment option for lumbar disc herniation (LDH) using the company's drug candidate, STA363. This minimally invasive treatment offers an efficient and simple solution for the millions of individuals suffering from pain, where pain medication or physical therapy have proven ineffective.
Read more
Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its year-end report for 2024. The report is available as an attached document and on the...
Stayble Therapeutics AB ("Stayble" or "the Company") today provides an update on the ongoing work to establish partnerships for the pain treatment STA363. The Company...
STA363 towards disc herniation place Stayble in a the forefront of injection-based, minimally invasive treatments for leg pain. As Stayble has developed successfully, the Company is competing to become the market leader in second-line therapies for pain caused by disc hernia.
About Stayble
We are currently conducting a clinical phase 1b study in disc herniation. Read more about the study below.
LDH CANDIDATEStayble is listed on Nasdaq First North under the ticker STABL. You will find all relevant information on the Stayble share in our Investors section.
Investors
The majority of patients suffering from unresolved disc hernia are not helped by conservative treatment with analgesics and physiotherapy. With no long term treatment options than surgery most of these patient continues to suffer without improvment.
Stayble’s product STA363 will bridge the gap between conservative and radical therapy to the benefit of millions of patients presently left on their own to cope with sustained and disabling pain.
About Stayble
